Pharma and Biotech
| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | n/a | n/a |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | n/a | n/a |
| Pr/Book | 65.3 |
| Latest | F'cast | |
|---|---|---|
| Revenue | n/a | n/a |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-20 | n/a | (0.01) | (2.80)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-21 | n/a | (3.96) | (2.40)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-22 | n/a | (0.96) | (0.30)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-23 | n/a | (1.76) | (0.50)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-24 | n/a | (2.19) | (0.60)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| £250,000 Funding Facility | 02-Apr-2026 | 07:00 | RNS |
| Progress on Launch of Biomarker Test in USA | 23-Feb-2026 | 07:00 | RNS |
| Patent Granted in Canada | 04-Feb-2026 | 07:00 | RNS |
No recent information was found.
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 2.20p |
| Change Today | 0.100p |
| % Change | 4.76 % |
| 52 Week High | 2.90 |
| 52 Week Low | 1.29 |
| Volume | 1,995,550 |
| Shares Issued | 396.39m |
| Market Cap | £8.72m |
| Beta | 0.02 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 13:50 | 12,801 @ 2.20p |
| 13:49 | 22,402 @ 2.19p |
| 13:05 | 904 @ 2.20p |
| 12:31 | 200,000 @ 2.19p |
| 12:04 | 2,000 @ 1.92p |
| Finance Director | Nigel Ronald Lee |
You are here: research